Objective: Weight loss and maintenance can be particularly challenging for postmenopausal women given the changes in body composition, metabolism, and lifestyle that can accompany the menopausal transition. Peptides mediating energy homeostasis (ghrelin, leptin, adiponectin, and insulin) may play an important role in the weight and body composition changes of postmenopausal women and may in turn be affected by hormone therapy (HT) use. This study examines how success with weight loss may be related to peptides mediating energy homeostasis and HT use.
W eight gain after menopause is common 1 and is associated with an increased likelihood of chronic health problems. 2 With the decline in estrogen levels, a postmenopausal woman's body often changes to include a higher composition of visceral fat. 1, 3 These changes in weight and body composition may be related to changes in levels of certain energy homeostasis peptides that may also occur with menopause. [4] [5] [6] Adverse changes in the energy homeostasis peptides in certain women may make it difficult for these women to lose weight and maintain weight loss, even with an intensive behavioral weight loss program. 7, 8 The current study evaluated levels of four peptides that mediate energy homeostasis: ghrelin, leptin, adiponectin, and insulin. [9] [10] [11] [12] Ghrelin increases food intake and decreases energy expenditure, 13, 14 whereas leptin has the opposite effect. [15] [16] [17] Adiponectin seems to induce weight loss primarily by increasing energy expenditure [18] [19] [20] ; it also decreases insulin resistance. 21 These peptides could influence weight change in different ways. Unfavorable changes in peptide levels with weight loss (increased ghrelin or decreased leptin) might make it more difficult to maintain weight loss. Furthermore, it may be possible that estrogen (Tprogesterone) hormone therapy (HT) administered to some postmenopausal women alters levels of the energy homeostasis peptides. Studies to date have shown that HT may impact energy homeostasis peptides, but results are inconsistent across studies. 22 For example, HT has been shown to decrease leptin levels in one population of postmenopausal women 23 but was shown to have no effect in others. 24, 25 To our knowledge, there have been no studies on the effects of initial administration and then discontinuation of HT on energy homeostasis peptides and weight change.
In this study, we sought to understand specifically how energy homeostasis peptides relate to increased body weight and difficulty with weight loss. We examined fasting blood levels of ghrelin, leptin, adiponectin, and insulin (at 0 and 18 mo) in 200 overweight, postmenopausal women to determine whether baseline or 0-18Ymonth change in these peptides are related to 0-18Ymonth (concurrent) and/or 18-30Ymonth (future) weight and/or body composition changes. In addition, we examined potential relationships between the energy homeostasis peptides and HT use patterns.
METHODS

Study design
To explore the relationships between weight change and peptides mediating energy homeostasis, data from the Women on the Move Through Activity and Nutrition (WOMAN) study were examined. The WOMAN study is a randomized clinical trial of a nonpharmacological lifestyle intervention of diet and physical activity to modify or reduce subclinical markers of cardiovascular disease. The WOMAN study design, including a description of the health education (HE) and lifestyle change (LC) groups, has been previously reported. 26 Primary goals for women in the LC group were to achieve 150 minutes/week of moderate physical activity, to follow an eating pattern low in total fat (17%) and saturated fat (G4%), and to achieve 10% weight loss. The study meal pattern emphasized grains, fruits, and vegetables as well as the use of functional foods, such as stanol-esterYcontaining margarine, increased sources of omega-3 fatty acids, and foods high in soluble fiber. There were significant differences in weight, waist circumference, nutrient intake, physical activity, and cardiovascular disease risk factors between the HE and LC groups at 18 months. 8 The total duration of the WOMAN study was 48 months, although the lifestyle intervention was stopped at approximately 36 months because of lack of continued funding.
Study population
A total of 508 postmenopausal women were recruited for the WOMAN study, primarily through direct mailing from selected zip codes in Allegheny County, PA, from April 2002 to October 2003. Eligibility criteria for enrollment into the study included having a waist circumference of 80 cm or greater, having a body mass index between 25 and 39.9 kg/m 2 , not currently taking lipid-lowering drugs, and having a low-density lipoprotein cholesterol level between 100 and 160 mg/dL, no physical limitations that would preclude walking, no known diabetes, and no diagnosed psychotic disorder or depression. The current analyses involved a convenience sample of women with data on ghrelin, leptin, adiponectin, and insulin at 0 and 18 months (n = 200, approximately the first 200 women enrolled in the study). Because of funding constraints, we did not perform ghrelin, leptin, and adiponectin assays for the remaining 308 women in the WOMAN study.
The first 200 women enrolled in the study are different from the subsequent 308 women enrolled in that a significantly greater percentage of the initial enrollees were on HT at baseline (79.5% vs 47.1%, respectively; P G 0.0001). After the results of the Women's Health Initiative (WHI) study were released, 27 new WOMAN study participants were not required to have been receiving HT at the time of randomization. However, most of these women had been receiving HT within 6 months before randomization. Also, more of the women in the present study were white (93% vs 85%; P = 0.01). The women in the present study are similar to the remaining participants in baseline weight (177.8 vs 181.8 lb; P = 0.09), waist circumference (106.0 vs 105.8 cm; P = 0.8), age (57.1 vs 56.9 y; P = 0.3), and percentage in lifestyle intervention group (49.5% vs 50.7%; P = 0.8).
All participants provided written informed consent forms, and all protocols were approved by the institutional review board at the University of Pittsburgh.
Measurement of peptides mediating energy homeostasis
Peptides were measured from fasting blood samples at baseline and 18 months; peptides assessed include ghrelin, leptin, adiponectin, and insulin. Total ghrelin levels were measured by commercial radioimmunoassay (Linco Research, Inc.). This assay uses 125 I-labeled ghrelin and a ghrelin antiserum to determine the level of total ghrelin by the double antibody/polyethylene glycol (PEG) technique. The limit of sensitivity is 100 pg/mL, and the response is linear to 10 ng/mL; the intra-assay coefficient of variation is 5.5%. Although only acylated ghrelin is bioactive, levels of total ghrelin may be a reasonable surrogate of the bioactive form because the ratio of total to bioactive ghrelin seems to remain fairly constant under conditions that affect ghrelin. 28 Adiponectin, leptin, and insulin levels were also assayed using commercial radioimmunoassay kits (Linco Research, Inc.). For leptin, the intra-assay and interassay coefficients of variation were 6.6% + 0.8% and 5.5% + 0.9%, respectively. Total (rather than high molecular weight) adiponectin levels were measured. Changes in peptide levels were calculated by subtracting baseline values from values measured at 18 months. We also calculated proportional changes in peptide levels by dividing the changes in peptide levels by the baseline values.
Weight and other anthropometric data
Weight, height, and waist circumference were measured at clinic visits at baseline and 18 and 30 months. Women were divided into quartiles of weight change for each time interval of interest in the study (0-18 and 18-30 mo). From 0 to 18 months, the quartiles of weight change were as follows: quartile 1, 0 to 18 lb gained; quartile 2, 0 to 7.6 lb lost; quartile 3, 7.6 to 18 lb lost; and quartile 4, 18 to 77.5 lb lost. From 18 to 30 months, the quartiles of weight change were as follows: quartile 1, 9.2 to 22 lb gained; quartile 2, 4.7 to 9.2 lb gained; quartile 3, 0 to 4.7 lb gained; and quartile 4, 0 to 30 lb lost.
Measurement of body composition
All participants in the WOMAN study underwent a total body dual-energy x-ray absorptiometry scan at 0 and 18 months. A total body dual-energy x-ray absorptiometry scan was performed using the pencil beam technology (QDR 1500, Hologic, Waltham, MA; enhanced whole body, software version 5.71). A standard soft tissue examination includes total body and regional measurements of trunk, arms, and legs to analyze body composition according to a threecompartment model (fat mass, lean tissue, and bone mineral content). We computed change in total body fat mass and percentage body fat between 0 and 18 months.
HT use
HT use and type of HT used were obtained through selfreport at each clinic visit. In addition, participants were classified as being either current HT users or nonusers at 0 and 18 months. Some women in this study discontinued HT after the WHI reports, 27 and variations in HT status at 0 and 18 months were compared with change in energy homeostasis peptides from 0 to 18 months. Study participants were classified as continuous HT users (on/on; n = 68), continuous HT nonusers (off/off; n = 38), or women who discontinued HT during the 18 months of follow-up (on/off; n = 91); most HT discontinuation occurred within the first 6 months after baseline. Three women who started HT between 0 and 18 months were excluded from this part of the analysis.
Other variables
The demographic characteristics, including age and race, of the participants were collected at baseline.
Statistical analyses
The baseline characteristics of the population studied were obtained by calculating mean values or percentages. Differences in peptides across quartiles of weight loss (at 0-18 and 18-30 mo) were evaluated using the nonparametric Jonkheere-Terpstra test and the linear trend test. The same analysis was performed with women stratified by baseline HT use status. Similarly, quartiles of body fat composition and percentage of body fat changes were analyzed by the Jonkheere-Terpstra and linear trend tests. Differences in HT status changes from 0 to 18 months (on/on, on/off, or off/off) for the energy homeostasis peptides were analyzed using analysis of variance. Additional exploratory analyses on the 18-30Ymonth weight change data, which were restricted only to women who lost 10 or more lb from 0 to 18 months (n = 85), were also performed.
Multiple linear regression models were used to predict change in energy homeostasis peptide (dependent variable) due to quartiles of weight change at 18 months (primary independent variable) and possible confounders (baseline energy homeostasis peptide value, age, baseline weight, race, and treatment group, ie, LC vs HE), HT status at baseline, and change in HT status from 0 to 18 months. Another multivariable model was created to explore how much of the variation in weight change at 0 to 18 months (dependent variable) was explained by changes in each of the peptides. Peptides were added to the model in a sequential fashion, starting with the peptide with the lowest P value as determined from univariable regression models. After addition of the peptides, the model was further adjusted for age, baseline weight, race, treatment group, and HT use, which were entered as a block of variables.
All statistical analyses were conducted using SAS version 9.1 (SAS Institute, Inc., Cary, NC).
RESULTS
Baseline peptides and weight change
At baseline, the mean body mass index was 30.3 kg/m 2 , weight was 177.8 lb, and waist circumference was 106.0 cm ( Table 1) . Baseline peptide levels were unrelated to weight change. There were no significant relationships seen between baseline levels of ghrelin, leptin, adiponectin, or insulin and successive quartiles of weight change from 0 to 18 or 18 to 30 months (data not shown). Results were the same when weight change was expressed as a continuous variable (data not shown).
Change in peptides and weight change from 0 to 18 months
In contrast to baseline peptide levels, 0-18Ymonth changes in peptides were significantly related to 0-18Ymonth weight change quartiles ( Fig. 1) . At 18 months, the average weight change was j10.5 lb (range, +18 to j77.5 lb). Ghrelin and adiponectin levels increased, and leptin and insulin levels decreased with greater weight loss. Results were the same when we examined proportional changes in peptide levels and when weight change was expressed as a continuous variable (data not shown).
Changes in peptides and body fat
Changes in leptin, adiponectin, and insulin levels from 0 to 18 months were each related to total body fat change (0-18 mo) quartiles. Change in ghrelin levels was not significantly related to the total body fat quartiles (P = 0.1 by linear trend test). Ghrelin, leptin, adiponectin, and insulin were all significantly related to quartiles of percentage total body fat change from 0 to 18 months (data not shown).
Effect of HT use on peptides and weight change
At baseline, 30.5% of the women in this study were taking oral estrogen only, and 37% were taking oral estrogen and progesterone. At 18 months, 20% were taking oral estrogen, and 10% were taking estrogen and progesterone. In stratified analyses, baseline hormone use did not affect the relationships between energy homeostasis peptides and weight change observed in the study overall. Only change in ghrelin was found to be different among the three HT status change groups (ie, on/on, on/off, and off/off; P = 0.03), with on/on women having a 31.5-pg/mL increase, on/off women, a 92-pg/mL increase; and off/off women, a 3.5-pg/mL decrease in ghrelin levels.
Multivariable models
In the multiple regression, weight change from 0 to 18 months remained associated with change in each energy homeostasis peptide after controlling for potential confounders (baseline energy homeostasis peptide value, age, baseline weight, race, treatment group, peptide therapy [HT] status at baseline, and change in HT status from 0 to 18 mo; Table 2 ). R 2 values for the models ranged from 0.09 (ghrelin) to 0.48 (leptin). In the multivariable model examining the predictors of weight change from 0 to 18 months, changes in leptin and adiponectin were found to be independently associated with weight change and remained so after potential confounders were added to the model. The R 2 for the final model was 0.71.
Change in peptides and weight change from 18 to 30 months
We also evaluated 0-18Ymonth change in peptides with 18-30Ymonth weight change ( Table 3) . The quartiles were different for the 18-30Ymonth weight change because most women gained weight and only those in the top quartile lost weight. It should also be noted that the women who lost weight from 18 to 30 months had lost the least amount of weight from 0 to 18 months (j15.9 vs j4.3 lb were lost from 0 to 18 mo for women in quartile 1 vs quartile 4 at 18 to 30 mo; P G 0.0001). In this analysis, only the 0-18Ymonth change in leptin was found to be significantly associated with 18-30Ymonth weight change. Women who lost weight from 18 to 30 months had the smallest decrease in leptin from 0 to 18 months. Results were the same when we examined proportional changes in peptide levels and also when we controlled for baseline weight (data not shown). Additional analyses that were limited only to those women who lost 10 lb or more from 0 to 18 months (n = 85) revealed no clear pattern between weight change from 18 to 30 months and change in any peptide from 0 to 18 months (data not shown). Results were also the same when weight change was expressed as a continuous variable (data not shown).
Significance of results
In this study of overweight, postmenopausal women, we found that with increasing amounts of weight loss, levels of ghrelin, leptin, adiponectin, and insulin changed in a linear fashion. The changes in energy homeostasis peptides that occur with weight change in this population have not yet been as well characterized in the literature. Also, the effect of HT discontinuation on energy homeostasis peptides has not been previously reported to our knowledge. We found that levels of ghrelin (but not the other peptides examined) increased more over 18 months in women who had discontinued HT over the same time period.
DISCUSSION
Baseline energy homeostasis peptide levels were unrelated to weight change at 0-18Y or 18-30Ymonth weight change intervals. Langenberg et al 11 have similarly reported that baseline ghrelin, leptin, and adiponectin levels do not predict long-term weight change, and they suggest that peptide levels actually follow an individual's weight trajectory rather than governing it. We also found that change in each of the peptide levels from 0 to 18 months was related to simultaneous 0-18Ymonth weight change. The trends were similar to those in previous studies, 10, 13, 29 with ghrelin and adiponectin levels increasing and leptin and insulin levels decreasing with weight loss. This simultaneous change in peptide level may be a direct result of a decrease in adipose tissue and energy reserves associated with weight loss.
The increasing levels of ghrelin seen with greater 0-18Ymonth weight loss (Fig. 1 ) may be the body's response to a decrease in baseline energy reserve level. With weight loss, the body assumes a state of starvation, and an increase in ghrelin leads to an increase in energy reserves. These actions by ghrelin may promote weight regain after weight loss. Also, the fact that ghrelin was the only peptide to not significantly change with total body fat change may be related to the fact that of the peptides studied, it interacts less directly with adipose tissue. 13, 15, 30, 31 Loss of adipose tissue with weight loss may explain the decrease in leptin values that were seen with increasing weight loss from 0 to 18 months (Fig. 1) . 8, [27] [28] [29] When examining 0-18Ymonth energy homeostasis peptide changes in conjunction with 18-30Ymonth weight change, only changes in leptin was associated with 18-30Ymonth weight change (changes in ghrelin and adiponectin were of borderline significance; Table 3 ). Women who lost weight from 18 to 30 months had the smallest decrease in leptin from 0 to 18 months. This suggests that maintaining relatively higher levels of the anorexigenic peptide leptin be associated with future weight loss because a decrease in leptin may promote weight regain. 32 A decrease in leptin when one is already resistant to its actions may make weight loss maintenance even more difficult. [33] [34] [35] When analyses were restricted to only women who lost 10 lb or more from 0 to 18 months, this pattern was not seen, which could suggest that initial weight loss (weight loss from 0 to 18 mo) may be an equally or more important factor in weight regain than are changes in leptin levels during the same period.
In our study, a woman's baseline HT status did not seem to affect relationships between energy homeostasis peptides and weight loss. Also, only change in ghrelin from 0 to 18 months was related to the changes in HT use. The fact that women on HT at baseline but off at 18 months had the greatest increase in ghrelin level (92 pg/mL) over 18 months is interesting because it may suggest that HT favorably decreases ghrelin levels and that discontinuing HT leads to an increase in ghrelin level. Ghrelin is known to promote food intake and decrease energy expenditure, 9, 14, 20 and thus, the increase in ghrelin level with discontinuation of HT could promote weight gain. Ghrelin has not been investigated in relation to HT as extensively as leptin, but Lambrinoudaki et al 25 found no relationship between HT administration and ghrelin levels in a study of 88 postmenopausal women. Our findings should be replicated in larger studies, as our findings with regard to ghrelin and HT could also be due to chance.
Changes in these energy homeostasis peptides with menopause and the decline in estrogen levels will be an interesting area for future research. For example, Hong et al 6 have shown that a decline in estrogen level correlates with changes in adipocytokines: increased tumor necrosis factor > and adiponectin levels and decreased leptin level. Others have likewise shown a decline in leptin level with decreased estrogen level after menopause. 36 Also, estrogen has been shown to enhance leptin sensitivity but decrease insulin sensitivity in the brain. 37 This study has a few limitations. There is a lack of premenopausal controls to compare with for potential differences in the energy homeostasis peptides after menopause. Also, we do not have data on serum estrogen levels, which could have been directly compared with levels of energy homeostasis peptides. In addition, as mentioned previously, the 200 women in this study are a convenience sample of the 508 women in the WOMAN study overall; these women differ from the overall WOMAN population in HT use, race, and perhaps in other, unmeasured ways. Because of our relatively small sample size, there is a chance that some of our findings are due to chance. Lastly, the results of this study are also not generalizable to populations other than postmenopausal women.
CONCLUSIONS
In conclusion, this study suggests that differing success with weight loss in postmenopausal women may be related in part to changes in levels of energy homeostasis peptides. Future studies should continue to address how changes in peptide levels relate to simultaneous and future weight trajectories. In addition, postmenopausal women who discontinued HT after the release of WHI results may have some changes in energy homeostasis peptides such as ghrelin that could hinder the ability to lose weight. The relationships between menopause, HT, and peptides mediating energy homeostasis should continue to be better characterized, as weight loss and maintenance remain challenging and a healthy body weight is important to positive health outcomes in postmenopausal women.
